Autopsy report · NCT05673109

A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer

“Subject benefit-risk ratio changes, sponsor decides to voluntarily terminate study”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 8 months before it stopped.
• 8 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Accutar Biotechnology Inc

Sponsor type

Industry

Conditions

Metastatic Castration Resistant Prostate Cancer

Interventions

AC176

Participants

8

Sites

5

Countries

China

Trials that died the same way

• Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated
  “Sponsor decision to terminate study.” (81% match in meaning)
• Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal Manifestations
  “Sponsor decision to terminate the study” (80% match in meaning)
• Study of RP-6306 With FOLFIRI in Advanced Solid Tumors
  “Sponsor decided to terminate the study” (79% match in meaning)
• A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer
  “Sponsor decision to early terminate the study” (79% match in meaning)
• A Study of AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer
  “Voluntarily terminate the study since the sponsor's development strategy was adjusted.” (79% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.